SBM Sirona Biochem Corp.

Sirona Biochem Engages Global Beauty Consulting

Sirona Biochem Engages Global Beauty Consulting

VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) has announced its partnership with Global Beauty Consulting – Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French formulator. GBC is currently developing an exclusive premium formulation for GlycoProteMimTM in anticipation of its launch in the first quarter of 2025.

GBC has a history of working with Sirona Biochem on the formulation of TFC-1067 for clinical development. This new venture is pivotal in building a brand and competitive product line that showcases GlycoProteMim's potent anti-aging benefits through its exclusive distribution brand Sirona LaboratoriesTM.

CEO Gaël Boutry has embraced the task of developing an unparalleled formula aimed at meeting the exacting demands of discerning cosmetic customers. “Our expertise teaches us that superior formulation is essential for securing a dedicated, repeat customer base for a new brand. We are in the process of creating a bespoke formula for GlycoProteMim, which we believe will lay the groundwork for forthcoming skincare offerings featuring GlycoProteMim”, reports Mr. Boutry.

Dr. Geraldine Deliencourt, Chief Scientific Officer at Sirona Biochem, stated, "With more than two decades of expertise and enriched by French craftsmanship, we are excited to utilize their meticulous service and attention to detail for the formulation of our first among many anticipated commercial products we plan to launch in Sirona Laboratories."

About Sirona Biochem Corp.

Sirona is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit .

About Global Beauty Consulting

Global Beauty Consulting offers a complete service in the cosmetics industry. We handle all aspects of your project through formulation, regulation, GMP implementation and assistance in the establishment of plants and laboratories. For more information, please visit or

For more information regarding this press release, please contact:

Investor Enquiries:

Email:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.



EN
15/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sirona Biochem Corp.

 PRESS RELEASE

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-13...

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology. About the Study The article, titled “TFC-1326 Compound Reduces Clinical Signs of Skin Aging: Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial,” highlights the groundbreaking efficacy of Sirona’s proprietary compound ...

 PRESS RELEASE

SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Produc...

SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear Shareholders, We are thrilled to provide an update on our efforts to bring our innovative cosmeceutical portfolio to global markets, with the initial launch set for early 2025. The commercialization of our first cosmetic product, a serum containing our GlycoProteMim™ active is progressing smoothly, in line with the timeline outlined in o...

 PRESS RELEASE

GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Res...

GlycoProteMim Featured in Stonegate Healthcare’s Latest Anti-Aging Research Report VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare's newly published research report, "Novel Treatments for Age-Related Skin Problems." The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market. The research highlights GlycoProteMim alongside other prominent ...

 PRESS RELEASE

Sirona Biochem Engages Stonegate Healthcare Partners

Sirona Biochem Engages Stonegate Healthcare Partners VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) has announced a partnership with Stonegate Healthcare Partners. Stonegate is a leading corporate advisory firm based in Dallas, Texas that offers research driven business development and investor outreach services. Leveraging Stonegate’s extensive global network of corporate and institutional investor relationships, Stonegate has begun an evaluation of Sirona’s anti-aging ingredient, GlycoProteMimTM, to effectively ass...

 PRESS RELEASE

SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024 VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear shareholders, We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem’s path forward. AGM Last week, during our Annual General Meeting (AGM), we successfully gained another year of backing for our management team. Although it's common for many shareholders to abstain from voting, we're pleased to report that we'...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch